Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25677316 | 0.91 | ALDH1A1 (0.32) | ALDH1A1TSHRTDP1 | |
| SCHEMBL25905265 | 0.91 | ALDH1A1 (0.35) | ALDH1A1TSHRTDP1 | |
| SCHEMBL9750744 | 0.86 | ALDH1A1 (0.35) | ALDH1A1TSHRTDP1 | |
| SCHEMBL17264065 | 0.82 | ALDH1A1 (0.37) | ALDH1A1TDP1CA12CA1CA2 | |
| SCHEMBL26211721 | 0.81 | OPRM1 (0.36) | ALDH1A1TSHRTDP1 | |
| SCHEMBL13175341 | 0.81 | ALDH1A1 (0.35) | ALDH1A1TSHRTDP1 | |
| SCHEMBL24694851 | 0.81 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL12022865 | 0.80 | ALDH1A1 (0.36) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL29690407 | 0.78 | ALDH1A1 (0.34) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL18811947 | 0.78 | ALDH1A1 (0.37) | ALDH1A1TSHRCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294869-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | TRAVERSA THERAPEUTICS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| EP-2240593-A2 | METHYLBUTANOL AS AN ADVANCED BIOFUEL | Synthetic Genomics, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009076480-A2 | METHYLBUTANOL AS AN ADVANCED BIOFUEL | SYNTHETIC GENOMICS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294869-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | POLN, SARNP, NCL | ALDH1A1 4308/4885TSHR 3741/4885TDP1 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.